Journal
DRUG DELIVERY
Volume 22, Issue 3, Pages 276-285Publisher
INFORMA HEALTHCARE
DOI: 10.3109/10717544.2013.876460
Keywords
Connexin-43; glioblasoma multiforme; monoclonal antibody; nanogels; targeted delivery
Categories
Funding
- RFBR [11-04-01806, 13-04-40202-H KOM]
- President of Russia for Young Scientists [MK-7114.2012.7]
- Russian Federation Ministry of Science and Education [11.G34.31.0004]
Ask authors/readers for more resources
Targeted drug delivery for brain tumor treatment is one of the important objectives in nanomedicine. Human glioblastoma is the most frequent and aggressive type of brain tumors. The preferential expression of membrane protein connexin 43 (Cx43) and brain-specific anion transporter (BSAT1) in the tumor and peritumoral area is a key component for targeted drug delivery. The purpose of this study was to design cisplatin-loaded nanogels conjugated with monoclonal antibodies to Cx43 and BSAT1 for treatment of intracranial gliomas 101/8. MRI volumetric analysis of tumor-bearing rats indicated significantly reduced tumor volume with cisplatin-loaded targeted-nanogel treatment compared to other formulations. The median survival of rats treated with targeted nanogels conjugated with specific mAbs against extracellular loops of Cx43 and BSAT1 were 27 and 26.6 days higher than that in control group, respectively. For the first time we demonstrated the efficiency of mAb-targeted cisplatin-loaded nanogels in the experimental model of glioma 101/8. This approach could facilitate the development of new drug delivery systems for the treatment of gliomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available